B7-H3 drug for recurrent brain tumor or brain metastases
Part of Cancer clinical trials.
This trial tests a drug called GSK5764227 (a B7-H3 targeted antibody-drug conjugate) in people whose glioblastoma has come back after standard treatment, or who have brain metastases that need surgery. The goal is to see if the drug can help shrink or control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a glioblastoma that has grown or returned after standard treatments, or you have a brain metastasis that needs surgery.
- You have tumor tissue from a prior biopsy or surgery that can be tested.
- You are age 18 or older.
- You are well enough to do daily activities on your own (ECOG score 0-2).
- Your blood cell counts, liver, kidney, and clotting function are within safe ranges.
- You are not pregnant, breastfeeding, and agree to use effective birth control during and for a time after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether customized drug screening on your tumor cells can help doctors choose the best treatment for you. Your tumor cells will be grown in the lab and tested against different drugs to find what works best, combined with short-course radiation therapy.
This trial tests an experimental drug, BMS-986504, for people with recurrent glioblastoma (a type of brain cancer). The drug targets a specific genetic change in the tumor. It aims to see if the drug can help shrink or slow the tumor.
This trial tests a stronger combination of treatments given after surgery for people with glioblastoma (GBM) that was only partially removed or that starts growing again quickly. It aims to see if this approach can help control the tumor better. You may be eligible if you are newly diagnosed, over 18, have good organ function, and do not have other serious health issues.
This trial tests a new drug, MT027, for people with high-grade glioma (a type of brain tumor) that has come back or continued to grow after standard treatment. The drug targets a protein called B7-H3 found on tumor cells. The goal is to see if it can help shrink tumors or slow the disease.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This trial tests a two-part treatment: an injected virus (DB107-RRV) plus an oral medication (DB107-FC) for people whose high-grade glioma (a type of brain tumor) has come back. The virus is designed to deliver a gene that makes the tumor sensitive to the oral drug, which then helps kill the cancer cells.
Hear when a new Glioblastoma (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.